Table 1 Dosages and duration of therapy at 7 years and survival outcomes at 5 years based on CML-AP diagnosis

From: Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

 

Hematologic status

Clonal evolution

Prior AP diagnosis

All patients diagnosed with CML-AP

 

QD (n = 67)

BID (n = 64)

QD (n = 55)

BID (n = 61)

QD (n = 34)

BID (n = 31)

QD (n =1 57)

BID (n = 160)

Average daily dose, mg (range)

119 (26–216)

108 (13–178)

94 (20–162)

97 (22–171)

106 (34–174)

87 (21–206)

NR

NR

Median duration of therapy, months (range)

8.3 (0.0–90.1)

9.2 (0.5–86.1)

21.9 (0.5–92.9)

20.7 (0.4–84.6)

16.9 (0.12–93.2)

20.3 (1.6–83.8)

15.4a (0.00–67.0)

12.5a (0.4–66.3)

Median duration of therapy excluding interruption, months (range)

7.4 (<0.1–89.1)

8.3 (0.5–85.4)

20.9 (0.5–92.9)

16.7 (0.3–83.7)

15.4 (0.2–91.4)

17.3 (1.6–81.7)

NR

NR

PFS, % (95% CI)

20.7 (11.5–31.9)

21.3 (10.2–35.2)

42.1 (27.4–56.1)

41.5 (25.0–57.2)

31.1 (15.8–47.8)

24.0 (7.1–46.1)

30.5 (22.6–38.5)

30.3 (20.9–39.6)

OS, % (95% CI)

32.8 (21.1–44.9)

45.6 (32.3–58.0)

52.6 (37.9–65.3)

67.9 (53.5–78.7)

54.3 (35.9–69.4)

60.2 (40.4–75.2)

45.0 (36.8–53.2)

57.6 (49.5–65.7)

  1. AP accelerated phase, BID twice a day, CI confidence interval, CML chronic myeloid leukemia, NR not reported, OS overall survival, PFS progression-free survival, QD once a day
  2. aDuration of therapy for entire CML-AP population calculated at 5 years
Back to article page